EASD 2023 In patients with T2D and HFmrEF/HFpEF, the treatment effect of dapagliflozin on the primary outcome was consistent across the number and most types of baseline glucose-lowering therapies.
ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.
ESC Congress 2023 After initiation of drugs, patients are on medications for years. But do the drugs still work? Milton Packer shares the outcomes of a randomized withdrawal trial with empagliflozin in patients with HF.
ESC Congress 2023 The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.
A meta-analysis showed that breast cancer survivors have an increased risk of CV death, HF, and AF, but not of CAD, MI, or ischemic stroke, compared with the general population.
Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.
What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.
ESC Congress 2023 In a large pooled analysis, intravenous ferric carboxymaltose reduced the risk of CV hospitalizations or CV death combined, but not mortality alone, in patients with HFrEF/HFmrEF and iron deficiency.
ESC Congress 2023 In HFrEF patients with iron deficiency, IV ferric carboxymaltose resulted in a modest albeit not statistically significant improvement in the hierarchical composite outcome of all-cause mortality, HF hospitalization, and change in exercise capacity.
ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.
ESC Congress 2023 Well before the next scheduled full ESC guideline on HF, new evidence of several RCTs that should change the management of patients with HF has become available. Therefore, the 2023 Focused Update was presented and published.
ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.